CVKD · Cadrenal Therapeutics, Inc.
$1.55
+0.02 (+1.31%)
At close · Aug 26
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern for one year after the financial statements are issued. Our unaudited financial statements for the quarter ended June 30, 2026 contain an explanatory paragraph with respect to this uncertainty. In addition, in connection with the filing of our Annual Report, our independent registered public accounting firm issued a report that included an explanatory paragraph with respect to this uncertainty. As such, we cannot conclude that such plans will be effectively implemented within one year after the date that the financial statements included in this Quarterly Report on Form 10Q are filed with the SEC and there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.46M
Shares
3.57M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.55
Open$1.56
Day$1.49–1.64
52W close$1.53–14.20
Avg vol 30d47K
Short int65K · 1.8% float · 1.8d
Short vol72%
Last earningsAug 11, 2025
DataAug 2024–Aug 2026
Filing10-Q · Aug 13
Raw chart and full-history price indicators begin at the captured split on Aug 20, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−34%
below
RSI (14)
26
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−81%
trailing
YTD return
−77%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$70.4K over 90 days · 100% sells
Short interest
Rising
1.82% of float · ▲ +6.5% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+24%
Y/Y
Free cash flow
$-12.6M
Balance sheet
$3.8M
net cash
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
12.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−34%
Bearish
RSI (14)
26
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Distributing
Net -$70.4K over 90 days · 100% sells
Short interest
Rising
1.82% of float · ▲ +6.5% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $14
vs 200-day avg -73%
vs 50-day avg -34%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents | $4.2M | as of early August 2026 | — |
| Private placement gross proceeds | $3M | Second Quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVKD
this stock
Cadrenal Therapeutics, Inc.
|
$5.46M | -77.1% | — | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 20, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVKD | -5.5% | -21.3% | -80.6% | -22.9% | -77.1% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -5.1% | -26.3% | -93.1% | -25.4% | -89.5% |
Key facts
CIK
1937993
CUSIP
127636207
13F (30d)
16 filings
16 filers
Visit website
Investor relations